Mesoblast (ASX:MSB) Announces U.S. Tariff Exemption for Allogeneic Cell Therapies
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Orthocell (ASX:OCC) secures FDA clearance for Remplir™, enabling entry into the US $1.6 billion nerve repair market.
US Masters Residential Property Fund (ASX:URF) announces an on-market buy-back of up to 172,720,501 units starting April 2025.
WT Financial Group Limited (ASX:WTL) forms Hubco, integrating three financial advice firms with strategic investment and growth plans.
Australian Rare Earths Limited (ASX:AR3) confirms uranium intersections in OV047, highlighting significant mineralisation potential and ongoing drilling efforts.
Magellan Financial Group (ASX:MFG) reports a decrease in AUM for March 2025, highlighting net outflows across retail and institutional segments.
Argent Minerals (ASX:ARD) announces high-grade gold assay results, confirming significant gold mineralisation at Trunkey Creek Project.
Benz Mining Corp (ASX:BNZ) announces a significant high-grade gold discovery at Glenburgh, validating its targeting model and expanding exploration potential.
Hillgrove Resources Limited (ASX:HGO) successfully raises $18 million through an oversubscribed equity offering to boost exploration initiatives.
Blackstone Minerals (ASX:BSX) reports significant copper-gold assay results from drillhole BRC-60, reinforcing the potential of its Mankayan project.